# US 2025/0375429 A1 · Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375429 A1
- Document ID: US20250375429A1
- Status: Published application
- Kind: A1
- Application number: 19/203,954
- Filed: 2025-05-09
- Published: 2025-12-11
- Earliest claimed: 2024-05-29
- Assignees: Smarter Not Harder, Inc.
- Applicants: Smarter Not Harder, Inc.
- Inventors: Theodore Borromeo ACHACOSO
- Web page: https://patentgrep.com/patent/US20250375429A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/42: Oxazoles
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition is provided and includes at least one orthosteric GABA receptor ligand that directly binds to at least one GABA-A receptor or at least one GABA-B receptor at the endogenous GABA binding site, and at least one non-orthosteric GABA receptor ligand that binds a site distinct from the endogenous GABA binding site on at least one GABA receptor type. This ensures the orthosteric and non-orthosteric ligands for each receptor type are co-present. The orthosteric and non-orthosteric ligands may be co-formulated for concurrent availability, such that the presence of the orthosteric ligand enables or enhances the therapeutic effect of the non-orthosteric ligand.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) at least one orthosteric GABA receptor ligand that directly binds to at least one GABA-A receptor or at least one GABA-B receptor at the endogenous GABA binding site; and
(b) at least one non-orthosteric GABA receptor ligand that binds a site distinct from the endogenous GABA binding site on at least one GABA receptor type, thereby ensuring the orthosteric and non-orthosteric ligands for each receptor type are co-present; wherein the orthosteric and non-orthosteric ligands are co-formulated for concurrent availability, such that the presence of the orthosteric ligand enables or enhances the therapeutic effect of the non-orthosteric ligand.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, further comprising an electrolyte.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the orthosteric ligand is a GABA-A or GABA-B receptor agonist.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the GABA-A or GABA-B ligand is selected from the group consisting of gamma-aminobutyric acid (GABA), muscimol, gaboxadol, baclofen, phenibut, progabide, picamilon, and salts or prodrugs thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the non-orthosteric ligand is selected from the group consisting of benzodiazepines, barbiturates, non-benzodiazepine hypnotic compounds, neurosteroids, ethanol, kava kavalactones, honokiol, valerian extracts, 3-hydroxybutyric acid (3-OHB), CGP7930, GS39783, and pharmaceutically acceptable analogs or derivatives thereof.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is formulated for at least one route of administration selected from the group consisting of transdermally, orally, transmucosally, rectally, vaginally, sublingually, buccally, by inhalation, by injection, via a patch, via nanoparticle delivery, or by nebulizer.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is presented as a single dosage unit that delivers one or more of the orthosteric and one or more of the non-orthosteric ligands concurrently or in controlled-release profiles designed to overlap in time in vivo.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein administering the composition results in a synergistic therapeutic effect, allowing a lower dose of at least one of the ligands compared to monotherapy with that ligand.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the orthosteric ligand and the non-orthosteric ligand both target GABA-A receptors, thereby enhancing GABA-A-mediated inhibitory tone.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the orthosteric ligand and the non-orthosteric ligand both target GABA-B receptors, thereby enhancing GABA-B-mediated inhibitory tone.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, further comprising one or more pharmaceutically acceptable excipients, carriers, or stabilizers that maintain the chemical stability and bioavailability of both ligands.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, further comprising at least one therapeutic agent selected from the group consisting of FDA-approved APIs, nutraceuticals, dietary supplements and homeopathic compositions.

### Claim 13 (depends on 1)

A method of treating a GABA-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1, such that the orthosteric ligand and the non-orthosteric ligand are delivered concurrently.

### Claim 14 (depends on 13)

The method of claim 13, wherein the GABA-related disorder is selected from the group consisting of anxiety, panic disorder, insomnia, epilepsy, acute agitation, severe anxiety, or delirium requiring rapid sedation.

### Claim 15 (depends on 13)

The method of claim 13, wherein the GABA-related disorder is muscle spasticity associated with multiple sclerosis, spinal cord injury, or neuropathic pain syndromes.

### Claim 16 (depends on 13)

The method of claim 13, wherein the composition is administered transdermally, orally, transmucosally, rectally, vaginally, sublingually, buccally, by inhalation, by injection, via a patch, via nanoparticle delivery, or by nebulizer, under conditions that ensure simultaneous bioavailability of the orthosteric and non-orthosteric ligands at the receptor site.

### Claim 17 (depends on 1)

A kit comprising:
(a) the pharmaceutical composition of claim 1; and
(b) instructions for use describing administration of said composition to treat a condition that benefits from enhanced therapeutic effect of the non-orthosteric ligand.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the instructions specify at least one dosage regimen for an indication selected from anxiety, insomnia, muscle spasticity, epilepsy, severe agitation or delirium, and further detail concurrent or sequential administration guidelines designed to preserve the obligate pairing of the orthosteric and non-orthosteric ligands.

### Claim 19 (depends on 17)

The kit of claim 17, wherein the pharmaceutical composition is provided in separate compartments for each active ingredient, the contents of which are combined prior to administration to ensure concurrent delivery, wherein the kit provides for titratable dosing of both ligands.

### Claim 20 (depends on 17)

The kit of claim 17, wherein the kit further includes at least one therapeutic agent selected from the group consisting of FDA-approved APIs, nutraceuticals, dietary supplements and homeopathic compositions.

### Claim 21

A method of formulating a pharmaceutical composition for providing an obligate pairing, the method comprising:
(a) selecting at least one orthosteric GABA receptor ligand as an active ingredient;
(b) selecting at least one non-orthosteric GABA receptor ligand as an active ingredient; and
(c) combining the selected ligands in a single pharmaceutical formulation such that a non-orthosteric ligand's modulatory effect is enabled or enhanced by the simultaneous presence of an orthosteric ligand.

### Claim 22 (depends on 21)

The method of claim 21, further comprising incorporating one or more excipients that stabilize each active ingredient, and adjusting release profiles so both ligands overlap in vivo.

### Claim 23 (depends on 21)

The method of claim 21, wherein the formulation is prepared for an administration route selected from the group consisting of transdermally, orally, transmucosally, rectally, vaginally, sublingually, buccally, by inhalation, by injection, via a patch, via nanoparticle delivery, or by nebulizer, and includes processing steps that ensure appropriate solubility or bioavailability of each ligand under that route.
